- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03874338
CLEAR SYNERGY Neutrophil Substudy
Studies on the Effects of Colchicine on Neutrophil Biology in Acute Myocardial Infarction: A Substudy of the CLEAR SYNERGY (OASIS 9) Trial
CLEAR SYNERGY is an international multi center 2x2 randomized placebo controlled trial of colchicine and spironolactone in patients with STEMI. Subjects enrolled in the main CLEAR SYNERGY trial will be asked to participate in this sub study (n=670) to undergo:
- Evaluation of markers of neutrophil activity at randomization (baseline) and 3 months follow-up in the colchicine versus placebo groups, and;
- Examination of clinical and genetic factors that determine heterogeneity of treatment response and distinguish colchicine responders from non- responders.
Participants undergo a blood draw at baseline and 3 months follow-up as part of the main trial, and participants who also participate in this sub study will have an additional 2 tablespoons of blood drawn.
The sub study objectives are to:
- Assess the effect of colchicine on neutrophil activation in response to STEMI.
- Examine clinical and genetic factors that determine heterogeneity of treatment response anddistinguish colchicine responders from non- responders.
- Explore the derivation of a risk score that includes markers of neutrophil activity and is associated with adjudicated MACE over 3 years after STEMI, and assess the impact of colchicine on the relation between this risk score and MACE.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Fatmira Curovic
- Phone Number: 347-602-2934
- Email: fatmira.curovic@nyumc.org
Study Contact Backup
- Name: Binita Shah, MD
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who are randomized to the drug RCT portion of the CLEAR SYNERGY (OASIS 9) trial will be eligible for participation in this Neutrophil biomarker substudy.
Exclusion Criteria:
- Use of anti-inflammatory agents (except aspirin)
- Active infection
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Placebo
|
Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design.
The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
|
Colchicine
|
Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design.
The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
soluble L-selectin
Time Frame: between baseline and 3 months
|
Change in soluble L-selectin between baseline and 3 mo after STEMI in the placebo vs. colchicine groups.
|
between baseline and 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Other soluble markers of neutrophil activity
Time Frame: between baseline and 3 months
|
Other markers of neutrophil activity will be evaluated at baseline and 3 months after STEMI (myeloperoxidase, matrix metalloproteinase-9, neutrophil gelatinase-associated lipocalin, neutrophil elastase, intercellular/vascular cellular adhesion molecules)
|
between baseline and 3 months
|
Markers of systemic inflammation
Time Frame: between baseline and 3 months
|
Markers of systemic inflammation will be evaluated at baseline and 3 months after STEMI (high sensitive CRP, IL-1β)
|
between baseline and 3 months
|
Neutrophil-driven responses that may further propagate injury
Time Frame: between baseline and 3 months
|
Neutrophil-driven responses that may further propagate injury will be evaluated at baseline and 3 months after STEMI (neutrophil extracellular traps, neutrophil-derived microparticles)
|
between baseline and 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Binita Shah, MD, NYU School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Gout Suppressants
- Colchicine
Other Study ID Numbers
- 18-01323
- 1R01HL146206 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STEMI - ST Elevation Myocardial Infarction
-
Stony Brook UniversityHennepin County Medical Center, MinneapolisUnknownAcute Coronary Syndrome | STEMI | NSTEMI - Non-ST Segment Elevation MI | Non ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Coronary Artery Thrombosis (Diagnosis) | Non ST Segment Elevation Acute Coronary Syndrome and other conditionsUnited States
-
Assiut UniversityNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
Assiut UniversityUnknownST-segment Elevation Myocardial Infarction (STEMI)
-
Hellenic Cardiovascular Research SocietyCompletedMyocardial Infarction | ST Segment Elevation Myocardial Infarction (STEMI)Greece
-
University College, LondonCompletedST-segment Elevation Myocardial Infarction (STEMI)Mauritius
-
A.H. TavenierIsalaCompletedSTEMI | STEMI - ST Elevation Myocardial InfarctionNetherlands
-
Peking University Third HospitalNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
The First Affiliated Hospital with Nanjing Medical...Completed
-
Samsung Medical CenterRainMed Medical; Shanghai Institute of Cardiovascular DiseasesActive, not recruitingST-segment Elevation Myocardial Infarction (STEMI)United States, China
-
Renmin Hospital of Wuhan UniversityThe First Affiliated Hospital of Dalian Medical University; Jiangxi Provincial... and other collaboratorsCompleted
Clinical Trials on Colchicine Pill
-
Sohag UniversityNot yet recruitingPeriprocedural Myocardial Injury | Periprocedural Myocardial Infarction
-
Beijing Anzhen HospitalNot yet recruitingST Elevation Myocardial Infarction | Acute Coronary Syndrome | Unstable Angina | Non ST Segment Elevation Myocardial Infarction | ColchicineChina
-
Assistance Publique - Hôpitaux de ParisHospices Civils de Lyon; Fonds de Dotation ACTIONNot yet recruiting
-
Population Health Research InstituteActive, not recruitingIntracranial HemorrhagesCanada
-
Bakulev Scientific Center of Cardiovascular SurgeryCompletedAtrial Fibrillation New Onset | Colchicine Adverse ReactionRussian Federation
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR)CompletedAtrial Fibrillation | Thoracic SurgeryCanada
-
Population Health Research InstituteRecruitingInflammation | Peripheral Arterial Disease | Atherosclerosis of ExtremitiesCanada
-
Wuhan Union Hospital, ChinaCompletedCoronary Artery Disease | Percutaneous Coronary InterventionChina
-
Eunice Kennedy Shriver National Institute of Child...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedObesity | Metabolic DiseaseUnited States
-
Montreal Heart InstituteCompletedMyocardial Infarction | Coronary Artery DiseaseCanada